37 studies on Ghrh secretagogue class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research provides a potential neurological explanation for the severe dyspepsia and appetite loss caused by cisplatin chemotherapy. It suggests that cisplatin treatment dampens the normal signaling response of ke…
The discovery of these novel, orally active growth hormone secretagogues represents a significant advancement in the field of endocrinology and drug development. Oral administration offers a more convenient and patien…
**NN703 demonstrates that oral GH secretagogue therapy is pharmacologically viable**, with a 30% bioavailability and 4.1-hour half-life that are compatible with once-daily dosing — a profile ipamorelin itself cannot a…
**The quantified SC50 of 214 nmol/L gives clinicians and researchers a concrete pharmacological benchmark** for designing ipamorelin dosing regimens — doses that push plasma concentrations well above this threshold sh…
**Glucocorticoid users do not need to forgo ipamorelin co-administration out of concern that the steroid will block GH release** — this study directly demonstrates the GH axis remains responsive. For clinicians managi…
**The practical takeaway for clinicians and researchers is that GHS peptides ipamorelin and GHRP-6 stimulate bone growth in adult female rats, but the mechanism is periosteal/dimensional expansion rather than increase…
This study reveals a critical GH-independent mechanism by which GHSs can increase body fat, potentially driven by increased feeding and altered metabolic signaling. This finding is highly significant for understanding…
This research provides a crucial mechanistic insight into how GHRPs stimulate growth hormone release, suggesting a significant interaction with the body's endogenous ghrelin system. Understanding this pathway could le…
This research significantly deepens our understanding of ghrelin's structure-activity relationship, particularly concerning its minimal active core and the critical role of specific amino acid positions. The identific…
This research highlights a successful strategy for designing highly potent growth hormone secretagogues by combining structural features from different active compounds. The discovery that re-introducing specific mole…
This research highlights Ipamorelin's potential to mitigate severe side effects of glucocorticoid therapy, which are widely used but often limited by their catabolic impact on bone and muscle. By demonstrating that Ip…
**Chronic ipamorelin pretreatment uniquely sensitises the pituitary somatotroph population** to respond to subsequent GHS or GHRH stimulation — a 'priming' phenomenon that does not occur after equivalent chronic GHRH …
This research successfully identified novel growth hormone secretagogues with significantly improved potency and, crucially, excellent oral bioavailability. The development of orally active GHS is a major step forward…
**Practitioners using ipamorelin or GHRP-6 to elevate IGF-1 should note that active or poorly-controlled type 1 diabetes may render these secretagogues incapable of raising IGF-1**, because the hepatic GH receptor pat…
This research is significant because it identifies a novel role for Ipamorelin beyond its known growth hormone-releasing effects, demonstrating its ability to directly stimulate insulin secretion. The finding that Ipa…
**Both ghrelin and its receptor are now fully characterised in a single teleost species**, enabling controlled mechanistic studies of the ghrelin/GHSR axis without cross-species extrapolation. The finding that **ipamo…
**Ipamorelin demonstrates functional GH-pathway metabolic activity** in a physiologically relevant catabolic model, supporting its potential utility for mitigating steroid-induced tissue wasting rather than merely sti…
**Sustained, multi-dose ipamorelin infusion is required to fully restore gut function after surgery** — a single bolus only partially addresses POI by accelerating initial transit without correcting the broader recove…
**Anti-doping laboratories now have a validated, multi-analyte LC-MS protocol** covering the eight most relevant GHRP candidates in a single urine assay, filling a critical gap left by GH immunoassays. The 20 h metabo…
These findings position ipamorelin as a potential therapeutic agent for managing **postoperative ileus**, a condition that complicates recovery from abdominal surgery. For individuals using peptides, this highlights a…
This advanced analytical method significantly enhances anti-doping efforts by providing a highly sensitive, robust, and expandable tool for detecting a broad panel of small prohibited peptides. The ability to detect t…
This advanced analytical method provides a crucial tool for anti-doping agencies to combat the illicit use of GHRPs in both equine and human sports. By enabling reliable and high-throughput detection, it helps ensure …
This trial suggests that **0.03 mg/kg ipamorelin twice daily is not an effective standalone treatment for postoperative ileus.** While the compound was safe and showed a trend toward faster recovery, the lack of stati…
These findings directly inform and improve anti-doping testing protocols. By identifying specific, long-lasting metabolites for each GHRP, labs can create more robust screening methods that significantly extend the de…
This research provides a foundational understanding of which structural parts of GHRPs like Ipamorelin are critical for their function. For peptide users, this knowledge explains why certain analogues are more or less…
For athletes and individuals using peptides, this technology has significant implications for the accuracy of anti-doping tests. The stabilization prevents the degradation of compounds like ipamorelin, meaning that ev…
This research reveals the specific chemical modifications being made to performance-enhancing drugs on the black market, providing critical intelligence for anti-doping agencies. The discovery of a 192-amino-acid GH v…
This groundbreaking discovery represents a significant new challenge for global anti-doping agencies and laboratories, as these glycine-modified GHSs are unlikely to be detected by current, standard screening protocol…
This research provides a proof-of-concept for a sophisticated drug delivery system in oncology, specifically for Boron Neutron Capture Therapy. By successfully attaching a stable boron cluster to peptides like Ipamore…
For clinicians and individuals managing hypogonadism, this review positions GHS like ipamorelin as a potential next-frontier adjunctive therapy to testosterone, specifically for targeting body composition issues like …
For anti-doping agencies, this research provides a validated method to significantly increase the speed and efficiency of screening for peptides like the TB-500 fragment. The ability to process **up to 96 samples simu…